NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis $5.05 +0.39 (+8.37%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.02▼$5.1650-Day Range$4.66▼$6.6552-Week Range$4.46▼$17.40Volume2,752 shsAverage Volume7,240 shsMarket Capitalization$5.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Pasithea Therapeutics alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Pasithea Therapeutics Stock (NASDAQ:KTTA)Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More KTTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTTA Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Stock Price Down 3.5%June 25, 2024 | investorplace.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 28, 2024 | globenewswire.comPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingMay 15, 2024 | msn.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024April 29, 2024 | globenewswire.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersFebruary 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.January 8, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 2, 2024 | msn.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | markets.businessinsider.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | seekingalpha.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 1, 2024 | benzinga.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesDecember 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 19, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 13, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?See More Headlines Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.06% Return on Assets-54.90% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$20,000.00 Price / Sales262.60 Cash FlowN/A Price / Cash FlowN/A Book Value$22.46 per share Price / Book0.22Miscellaneous Outstanding Shares1,040,000Free Float873,000Market Cap$5.25 million OptionableNot Optionable Beta0.75 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder, MD & Executive Chairman Comp: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Comp: $480kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Comp: $345.94kDr. Graeme Currie Ph.D. (Age 57)Chief Development Officer Comp: $346.62kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics Key CompetitorsVaccinexNASDAQ:VCNXBioVieNASDAQ:BIVIMinerva NeurosciencesNASDAQ:NERVHCW BiologicsNASDAQ:HCWBCytoMed TherapeuticsNASDAQ:GDTCView All Competitors KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed this year? Pasithea Therapeutics' stock was trading at $7.40 at the beginning of 2024. Since then, KTTA shares have decreased by 31.8% and is now trading at $5.05. View the best growth stocks for 2024 here. How were Pasithea Therapeutics' earnings last quarter? Pasithea Therapeutics Corp. (NASDAQ:KTTA) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($3.70) EPS for the quarter. When did Pasithea Therapeutics' stock split? Shares of Pasithea Therapeutics reverse split before market open on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KTTA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
